Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells

Chimeric antigen receptor (CAR) T cell therapy targeting CD19 elicits remarkable clinical efficacy in B cell malignancies, but many patients relapse owing to failed expansion and/or progressive loss of CAR-T cells. We recently reported a strategy to potently restimulate CAR-T cells in vivo, enhancing their functionality by administration of a vaccine-like stimulus comprised of surrogate peptide ligands for a CAR linked to a lymph node-targeting amphiphilic PEG-lipid (amph-vax). Here we demonstrate a general strategy to discover and optimize peptide mimotopes enabling amph-vax generation for any CAR. We use yeast surface display to identify peptide binders to FMC63 (the scFv used in clinical CD19 CARs), which are then subsequently affinity matured by directed evolution. CAR-T vaccines using these optimized mimotopes triggered marked expansion and memory development of CD19 CAR-T cells in both syngeneic and humanized mouse models of B-acute lymphoblastic leukaemia/lymphoma, and enhanced control of disease progression compared with CD19 CAR-T-only-treated mice. This approach enables amph-vax boosting to be applied to any clinically relevant CAR-T cell product.

Authors

Institutions

Publication Details

Journal
Nature Biomedical Engineering
Published
2025-08-25
DOI
https://doi.org/10.1038/s41551-025-01470-0
Citations
3
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
3.14
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells

Norbert Frey, Roberto Chiarle, Anna Romanov, Wuhbet Abraham et al.
3 citations
Nature Biomedical Engineering
CAR-T cell therapy research
3.14
article

Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells

Norbert Frey, Roberto Chiarle, Anna Romanov, Wuhbet Abraham, Leyuan Ma, Guido Ghilardi, Benjamin Cossette, Luca Paruzzo, Duncan M. Morgan, Beatriz Gonçalves, Heikyung Suh, Naveen K. Mehta, Stephan Kadauke, Parisa Yousefpour, Stephan A. Grupp, Stephen J. Schuster, Tomasz M. Grzywa, Elisa Bergaggio, Darrell J. Irvine, Marco Ruella, Libin Zhang, Regina M. Myers, Alexandra Neeser, Ranjani Ramasubramanian, Aj Cozzone, K. Dane Wittrup, Ina Sukaj, Ryan Tannir
article en
3 citations

Abstract

Chimeric antigen receptor (CAR) T cell therapy targeting CD19 elicits remarkable clinical efficacy in B cell malignancies, but many patients relapse owing to failed expansion and/or progressive loss of CAR-T cells. We recently reported a strategy to potently restimulate CAR-T cells in vivo, enhancing their functionality by administration of a vaccine-like stimulus comprised of surrogate peptide ligands for a CAR linked to a lymph node-targeting amphiphilic PEG-lipid (amph-vax). Here we demonstrate a general strategy to discover and optimize peptide mimotopes enabling amph-vax generation for any CAR. We use yeast surface display to identify peptide binders to FMC63 (the scFv used in clinical CD19 CARs), which are then subsequently affinity matured by directed evolution. CAR-T vaccines using these optimized mimotopes triggered marked expansion and memory development of CD19 CAR-T cells in both syngeneic and humanized mouse models of B-acute lymphoblastic leukaemia/lymphoma, and enhanced control of disease progression compared with CD19 CAR-T-only-treated mice. This approach enables amph-vax boosting to be applied to any clinically relevant CAR-T cell product.

Nature Biomedical Engineering
University of the Sciences (US), Scripps Research Institute (US), Boston Children's Hospital (US), Children's Hospital of Philadelphia (US), Howard Hughes Medical Institute (US), Harvard University (US), Scripps College (US), Ragon Institute of MGH, MIT and Harvard (US), IIT@MIT (US), Penn Center for AIDS Research (US), Allen Institute (US), Koch Institute for Integrative Cancer Research At MIT (US), University of Turin (IT), Massachusetts Institute of Technology (US), University of Pennsylvania (US)
Openalex Percentile: Top 7%
CAR-T cell therapy research
3.14
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.